1. Home
  2. Directory
  3. Arkansas
  4. Jonesboro
  5. Podiatrist
  6. NPI Profile
  7. Prescriptions 1760613004

DR. ERIK ROSENLOF D.P.M.
Prescription History 1760613004
Podiatrist - Foot & Ankle Surgery in Jonesboro, AR

NPI Status: Active since August 04, 2009

Contact Information

637 E MATTHEWS AVE
JONESBORO, AR
ZIP 72401
Phone: (870) 931-3338
Fax: (870) 935-9084

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. ERIK ROSENLOF D.P.M., an active Foot & Ankle Surgery specialist practicing in Jonesboro, AR. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 71 documented patient claims. Among these therapy options, the most frequently utilized medication is Sulfamethoxazole-Trimethoprim, which accounts for 21 claims alone.

Medication Index

Cilostazol

Generic Formulation: CilostazolSpecialty: Podiatry
Provider Metrics Summary
Total Claims 11
30-Day Fills 21.0
Days Supply 630
AR State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills36.5
Peer Average Days Supply1,084
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $886.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$80.62

State Avg Cost Per Claim

$28.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoline and tetrazole derivative that acts as a phosphodiesterase type 3 inhibitor, with anti-platelet and vasodilating activity. It is used in the treatment of PERIPHERAL VASCULAR DISEASES; ISCHEMIC HEART DISEASE; and in the prevention of stroke.

Therapeutic Applications

Cilostazol is used to improve the symptoms of a certain blood flow problem in the legs (intermittent claudication). Cilostazol can decrease the muscle pain/cramps that occur during exercise/walking. Claudication pain is caused by too little oxygen getting to the muscles. Cilostazol can increase blood flow and the amount of oxygen that gets to the muscles. Cilostazol is an antiplatelet drug and a vasodilator. It works by stopping blood cells called platelets from sticking together and prevents them from forming harmful clots. It also widens blood vessels in the legs. Cilostazol helps the blood to move more easily and keeps blood flowing smoothly in your body.

Gabapentin

Generic Formulation: GabapentinSpecialty: Podiatry
Provider Metrics Summary
Total Claims 14
30-Day Fills 16.0
Days Supply 480
AR State Average Benchmarks
Peer Average Claims129.0
Peer Average 30-Day Fills193.2
Peer Average Days Supply5,705
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 89.1% less volume than the regional standard for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $308.92 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.07

State Avg Cost Per Claim

$24.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Hydrocodone-Acetaminophen

Generic Formulation: Hydrocodone/AcetaminophenSpecialty: Podiatry
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 93
AR State Average Benchmarks
Peer Average Claims131.0
Peer Average 30-Day Fills131.8
Peer Average Days Supply2,950
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 89.3% less volume than the regional standard for practitioners inside AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $165.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.81

State Avg Cost Per Claim

$24.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to relieve moderate to severe pain. It contains an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen). Hydrocodone works in the brain to change how your body feels and responds to pain. Acetaminophen can also reduce a fever.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Podiatry
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 227
AR State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills27.7
Peer Average Days Supply322
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $179.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.57

State Avg Cost Per Claim

$6.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Vancomycin Hcl

Generic Formulation: Vancomycin HclSpecialty: Podiatry
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 78
AR State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills13.4
Peer Average Days Supply44
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,334.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$303.13

State Avg Cost Per Claim

$100.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.

Therapeutic Applications

Vancomycin is an antibiotic used to treat infections. This form of vancomycin is used to treat a certain intestinal condition (colitis) caused by bacteria. This condition causes diarrhea and stomach/abdominal discomfort or pain. When vancomycin is taken by mouth, it stays in the intestines to stop the growth of certain bacteria that cause these symptoms. This antibiotic treats only bacterial infection in the intestines. It will not work for bacterial infections in any other part of the body or for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. ERIK ROSENLOF D.P.M. provides transparency into local medical care patterns within Jonesboro, AR.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Foot & Ankle Surgery** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.